Lisata Therapeutics, Inc. is a Nasdaq-traded biotechnology company focused on developing innovative treatments for cardiovascular and autoimmune diseases, with a mission to improve patient care globally.

Lisata Therapeutics, a biopharmaceutical company, has reported its financial performance, with a market capitalization of $20.9 million and a stock price of $2.52 per share.

Lisata Therapeutics’ stock has experienced significant fluctuations, closing at $2.30 on May 6, 2025, with a market capitalization of $20.76 million and a price-to-earnings ratio of -1.

Lisata Therapeutics Inc. will report its Q1 2025 financial results on May 8, 2025, and host a conference call to provide a business update and discuss its pipeline and market position.